These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 13678480)

  • 1. Epoetins: differences and their relevance to immunogenicity.
    Haselbeck A
    Curr Med Res Opin; 2003; 19(5):430-2. PubMed ID: 13678480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure red-cell aplasia "epidemic"--mystery completely revealed?
    Locatelli F; Del Vecchio L; Pozzoni P
    Perit Dial Int; 2007 Jun; 27 Suppl 2():S303-7. PubMed ID: 17556324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure red-cell aplasia and epoetin therapy.
    Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
    N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin-associated pure red cell aplasia: past, present, and future considerations.
    McKoy JM; Stonecash RE; Cournoyer D; Rossert J; Nissenson AR; Raisch DW; Casadevall N; Bennett CL
    Transfusion; 2008 Aug; 48(8):1754-62. PubMed ID: 18482185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
    Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E;
    Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.
    Boven K; Stryker S; Knight J; Thomas A; van Regenmortel M; Kemeny DM; Power D; Rossert J; Casadevall N
    Kidney Int; 2005 Jun; 67(6):2346-53. PubMed ID: 15882278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
    Cournoyer D; Toffelmire EB; Wells GA; Barber DL; Barrett BJ; Delage R; Forrest DL; Gagnon RF; Harvey EA; Laneuville P; Patterson BJ; Poon MC; Posen GA; Messner HA;
    J Am Soc Nephrol; 2004 Oct; 15(10):2728-34. PubMed ID: 15466278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?
    Hermeling S; Schellekens H; Crommelin DJ; Jiskoot W
    Pharm Res; 2003 Dec; 20(12):1903-7. PubMed ID: 14725351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing the immunogenicity of therapeutic proteins.
    Schellekens H
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi3-9. PubMed ID: 15958824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.
    Boven K; Knight J; Bader F; Rossert J; Eckardt KU; Casadevall N
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii33-40. PubMed ID: 15824129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.
    Casadevall N
    Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii37-41. PubMed ID: 14608000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
    Opatrný K
    Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia.
    Schellekens H
    Curr Med Res Opin; 2003; 19(5):433-4. PubMed ID: 13678481
    [No Abstract]   [Full Text] [Related]  

  • 15. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins.
    Weber G; Gross J; Kromminga A; Loew HH; Eckardt KU
    J Am Soc Nephrol; 2002 Sep; 13(9):2381-3. PubMed ID: 12191983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
    Bennett CL; Cournoyer D; Carson KR; Rossert J; Luminari S; Evens AM; Locatelli F; Belknap SM; McKoy JM; Lyons EA; Kim B; Sharma R; Costello S; Toffelmire EB; Wells GA; Messner HA; Yarnold PR; Trifilio SM; Raisch DW; Kuzel TM; Nissenson A; Lim LC; Tallman MS; Casadevall N
    Blood; 2005 Nov; 106(10):3343-7. PubMed ID: 16099877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure.
    Lim LC
    Hematology; 2005 Jun; 10(3):255-9. PubMed ID: 16019474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin-Associated PRCA: Still an Unsolved Mystery.
    Schellekens H; Jiskoot W
    J Immunotoxicol; 2006 Sep; 3(3):123-30. PubMed ID: 18958692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition and identification of UV-absorbing leachables in EPREX pre-filled syringes: an unexpected occurrence at a formulation-component interface.
    Pang J; Blanc T; Brown J; Labrenz S; Villalobos A; Depaolis A; Gunturi S; Grossman S; Lisi P; Heavner GA
    PDA J Pharm Sci Technol; 2007; 61(6):423-32. PubMed ID: 18410043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework.
    Jacob S; Nichols J; Macdougall IC; Qureshi Z; Chen B; Yang YT; Norris LB; Bennett CL
    Am J Ther; 2018; 25(6):e670-e674. PubMed ID: 30169374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.